CONSOLIDATED STATEMENTS OF EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Members' Interest	[1]	Common Stock	Common Stock Class A Common Stock	Common Stock Class B-1 Common Stock	Common Stock Class B-2 Common Stock	Additional Paid-in Capital	(Accumulated Deficit) Retained Earnings	Accumulated Other Comprehensive Loss	Total Stockholders'/Members' Equity	Noncontrolling Interest
Beginning Balance at Feb. 01, 2020	$ 561,061	$ 1,358,130							$ (780,466)	$ (8,273)	$ 569,391	$ (8,330)
Equity-based compensation expense (Note 12)	12,915	9,757						$ 3,158			12,915
Repurchase of equity	(104)	(104)									(104)
Net income (loss)	(31,736)								(26,483)		(26,483)	(5,253)
Foreign currency translation adjustment, net of tax	(905)									(905)	(905)
Unrealized loss on derivatives, net of tax (Note 9)	(86)									(86)	(86)
Losses on derivatives reclassified to income, net of tax (Note 9)	7,989									7,989	7,989
Contributions of Senior Notes (Note 8)	573,934							573,934			573,934
Conversion to Delaware corporation(Note 1)		$ (1,367,783)		$ 209				582,876	784,698
Conversion to Delaware corporation (Note1) (in shares)					171,224	37,791	37,791
Issuance of common stock	932,197			55				932,142			932,197
Issuance of common stock (in shares)					55,200
Ending Balance at Jan. 30, 2021	2,055,265			264				2,092,110	(22,251)	(1,275)	2,068,848	(13,583)
Ending Balance (in shares) at Jan. 30, 2021					226,424	37,791	37,791
Equity-based compensation expense (Note 12)	45,603							45,603			45,603
Net income (loss)	159,805								164,417		164,417	(4,612)
Foreign currency translation adjustment, net of tax	(963)									(963)	(963)
Unrealized loss on derivatives, net of tax (Note 9)	0
Losses on derivatives reclassified to income, net of tax (Note 9)	0
Issuance of restricted stock awards (in shares)					55
Issuance of common stock	(3,891)			1				(3,892)			(3,891)
Issuance of common stock (in shares)					708
Ending Balance at Jan. 29, 2022	2,255,819			265				2,133,821	142,166	(2,238)	2,274,014	(18,195)
Ending Balance (in shares) at Jan. 29, 2022					227,187	37,791	37,791
Equity-based compensation expense (Note 12)	61,355							61,355			61,355
Net income (loss)	89,910								90,801		90,801	(891)
Foreign currency translation adjustment, net of tax	194									194	194
Unrealized loss on derivatives, net of tax (Note 9)	(2,180)									(2,180)	(2,180)
Losses on derivatives reclassified to income, net of tax (Note 9)	127									127	127
Investment in veterinary joint venture (Note 1)	(21,226)							(40,312)			(40,312)	$ 19,086
Issuance of common stock	(2,521)			1				(2,522)			(2,521)
Issuance of common stock (in shares)					1,151
Ending Balance at Jan. 28, 2023	$ 2,381,477			$ 266				$ 2,152,342	$ 232,967	$ (4,098)	$ 2,381,477
Ending Balance (in shares) at Jan. 28, 2023					228,338	37,791	37,791

[1] Balances prior to the Company's conversion to a Delaware corporation were reclassified to additional paid-in capital to give effect to the organizational transactions described in Note 1.